IQAI was created to accelerate the translation and commercialisation of proven imaging technologies, from the laboratory to routine clinical use, that have potential to dramatically impact the quality of life for patients facing brain tumours and other chronic diseases.
Brain tumour patients and especially those diagnosed with glioblastoma multiforme (GBM) for example face a dismal prognosis. Despite tremendous global efforts that span decades, only incremental improvements have been made in survivability and progression free survival.
The unmet clinical need of GBM and other diseases motivates IQAI to continuously innovate and deliver validated products that benefit patients. Since its inception, the company has aggressively proliferated its product portfolio, accelerated product and technology development, and obtained market clearance for new global territories.